Zentek Announces Grant of Stock Options

Rhea-AI Summary

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has announced the granting of 1,300,000 stock options to its directors, officers, and employees. These options are exercisable at $4.25 per share for a period of three to five years, with a vesting schedule of one-third immediately, one-third after six months, and the final third after twelve months. The company focuses on next-gen healthcare solutions and is commercializing ZENGuard™, a patent-pending antimicrobial coating with 99% efficacy against pathogens, including COVID-19.

Positive

• Granting of 1,300,000 stock options indicates confidence in company growth.
• ZENGuard™ shows 99% antimicrobial activity, enhancing product potential.

Negative

• None.

GUELPH, ON / ACCESSWIRE / January 14, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSXV:ZEN)(OTC PINK:ZENYF), an IP development and commercialization company focused on next-gen healthcare solutions, announces the granting of 1,300,000 options to directors, officers and employees of the company exercisable at a price of $4.25 per common share for a period of three to five years from the date of the grant. The options will vest one-third on the date of grant, one-third after six months of the date of grant and one-third after 12 months of the date of grant.

About Zentek Ltd.

Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com

To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.ca.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.

View source version on accesswire.com:
https://www.accesswire.com/683633/Zentek-Announces-Grant-of-Stock-Options

FAQ

What is the stock option grant by Zentek Ltd.?

Zentek Ltd. granted 1,300,000 stock options to directors, officers, and employees, exercisable at $4.25 per share.

What is ZENGuard™ and its significance?

ZENGuard™ is a patent-pending antimicrobial coating developed by Zentek, showing 99% efficacy against pathogens including COVID-19.

How long are the options valid for Zentek Ltd.?

The stock options are valid for three to five years from the date of grant.

When do the stock options granted by Zentek Ltd. vest?

The options vest in three installments: one-third immediately, one-third after six months, and one-third after twelve months.

What are the stock symbols for Zentek Ltd.?

The stock symbols for Zentek Ltd. are TSXV:ZEN and OTC PINK:ZENYF.